Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

News

Year

How tiny golden crystals reverse damage from Parkinson’s disease, multiple sclerosis

StudyFinds

February 21, 2024

Phase 2 trial findings support larger study of CNM-Au8 for Parkinson’s

Parkinson's News Today

February 19, 2024

Daily Dose of Gold Nanocrystals May Reverse Neurological Disabilities

The Science Times

February 15, 2024

Daily Dose of Gold May Reverse Parkinson's and Multiple Scleroseis Symptoms

Newsweek

February 14, 2024

Nanoparticles Detect Brain Target Engagement

AzoNano

February 14, 2024

Daily gold nanocrystal drink promising as MS and Parkinson’s treatment

New Atlas

February 13, 2024

Gold nanoparticles reverse brain deficits in multiple sclerosis, Parkinson’s

UTSW Newsroom

February 13, 2024

VISIONARY-MS Trial Reports CNM-Au8 Improves Vision and Cognition in Multiple Sclerosis

NeurologyLive

January 9, 2024

ALS Agent CNM-Au8 Reduces NfL, Positive CLEAR-MIND Results, Decreased Learning Abilities in Narcolepsy

NeurologyLive

January 6, 2024

CNM-Au8 Reduces Neurofilament Light and Improves Survival in ALS, HEALEY-ALS Open-Label Extension Data Suggests

Neurology Live

January 3, 2024

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2024 Clene Nanomedicine, Inc. - All rights reserved | PRIVACY POLICY | TERMS OF USE